Development of a core outcome set and core measurement set for kangaroo mother care: a study protocol.

BMJ Open

Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, Sichuan, China

Published: January 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Kangaroo mother care (KMC) is a care of preterm and low birthweight infants carried skin-to-skin contact with the mother's chest and breastfeeding when possible. KMC has been proven to reduce mortality and morbidity in these infants. However, research on KMC has been limited by significant variability and inconsistency in reported outcomes across studies. These discrepancies hinder the inclusion of KMC clinical research in systematic reviews or meta-analyses, reducing its research value, leading to resource wastage and raising concerns about selective reporting biases. A core outcome set (COS), which defines a list of critical outcomes, can help harmonise the outcomes reported across studies in the same healthcare field. Further, how these outcomes should be measured and/or reported is defined in a core measurement set (CMS). This study aims to develop both a COS and a CMS for KMC to standardise outcome reporting, improve the quality assessments in clinical trials and facilitate data integration. This protocol outlines the methodology for developing a COS and CMS for KMC.

Methods And Analysis: The development of the COS and CMS for KMC will follow six phases: (1) a systematic review, (2) semistructured interviews, (3) merging outcomes, (4) two/three rounds of international Delphi survey, (5) a consensus meeting and (6) development of the CMS. In phases 1 and 2, we will conduct a systematic review and semistructured interviews to identify potential core outcomes and measurements, which will form an initial outcome pool. In phase 3, these outcomes will be categorised into domains based on the core outcome measures for effectiveness (COMET) classification, creating a long list of outcomes for the Delphi survey. In phase 4, the Delphi survey will involve two/three rounds with key stakeholders, including neonatal clinical experts (including doctors and nurses), users of COS (including editors, public health experts, experts in evidence-based medicine and researchers), parents of neonates and policymakers, to refine the candidate core outcomes and measurements. In phase 5, an online consensus meeting with representatives of all stakeholders will finalise the COS. In phase 6, the CMS will be following Consensus-based Standards for the selection of health Measurement Instruments guidelines, which involve conceptual considerations, finding existing outcome measurement instruments, assessing their quality and selecting appropriate instruments for the COS. Parents of neonates will participate in phases 2, 4 and 5.

Ethics And Dissemination: Ethical approval of this study has been granted by the Medical Ethics Committee of West China Second University Hospital (Medical Research 2024 ethics approval no. 167). The finalised COS and CMS will be disseminated through publication in peer-reviewed journals.

Trial Registration Number: We have registered the COS in the COMET database (http://www.comet-initiative.org/Studies/Details/2940).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749680PMC
http://dx.doi.org/10.1136/bmjopen-2024-089476DOI Listing

Publication Analysis

Top Keywords

cos cms
16
core outcome
12
delphi survey
12
outcomes
9
cos
9
will
9
outcome set
8
core measurement
8
measurement set
8
kangaroo mother
8

Similar Publications

Human pluripotent stem cell (hPSC)-derived cardiac organoids (COs) are the most recent three-dimensional tissue structure that mimics the human heart's structure and functionality for modeling heart development and disease. Fluorescent labeling and imaging are commonly utilized to characterize the cellular information in COs. However, the additional step of fluorescence labeling and imaging is time-consuming, inefficient, and typically for end-timepoint characterization.

View Article and Find Full Text PDF

Early Atrial Remodeling Drives Arrhythmia in Fabry Disease.

Circ Arrhythm Electrophysiol

July 2025

Institute of Cardiovascular Sciences, Birmingham, United Kingdom (A.R., C.O.S., L.P., M.J.C., H.S.C., A.A., A.M.P., C.H., A.P.H., D.P., J.N.T., K.G., R.P.S.).

Background: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by α-Gal A (α-galactosidase A) deficiency, resulting in multiorgan accumulation of sphingolipid, namely globotriaosylceramide. This triggers ventricular myocardial hypertrophy, fibrosis, and inflammation, driving arrhythmia and sudden death. Atrial fibrillation is common, yet the cellular mechanisms accounting for this are unknown.

View Article and Find Full Text PDF

Purpose: To review candidate outcome measurement instruments (OMIs) for the core outcome set (COS) for brachial plexus injury (BPI) and identify those with the strongest measurement properties.

Methods: We conducted a PRISMA-compliant systematic review to identify studies on the measurement properties of domain-specific OMIs for adult BPI. OMIs with adequate content validity were further evaluated.

View Article and Find Full Text PDF

Development and application of 3D cardiac tissues derived from human pluripotent stem cells.

Drug Metab Pharmacokinet

February 2025

Department of Clinical Regenerative Medicine, Fujita Medical Innovation Center Tokyo, Fujita Health University, Tokyo, Japan; Department of Cardiology, Keio University School of Medicine, Tokyo, Japan. Electronic address:

Recently human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have become an attractive platform to evaluate drug responses for cardiotoxicity testing and disease modeling. Moreover, three-dimensional (3D) cardiac models, such as engineered heart tissues (EHTs) developed by bioengineering approaches, and cardiac spheroids (CSs) formed by spherical aggregation of hPSC-CMs, have been established as useful tools for drug discovery and transplantation. These 3D models overcome many of the shortcomings of conventional 2D hPSC-CMs, such as immaturity of the cells.

View Article and Find Full Text PDF

Development of a core outcome set and core measurement set for kangaroo mother care: a study protocol.

BMJ Open

January 2025

Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, Sichuan, China

Background: Kangaroo mother care (KMC) is a care of preterm and low birthweight infants carried skin-to-skin contact with the mother's chest and breastfeeding when possible. KMC has been proven to reduce mortality and morbidity in these infants. However, research on KMC has been limited by significant variability and inconsistency in reported outcomes across studies.

View Article and Find Full Text PDF